Studies of Elevated Parathyroid Activity
Hyperparathyroidism, Hypercalcemia, Parathyroid Neoplasm, Multiple Endocrine Neoplasia, MEN1
ClinicalTrials.gov recordTREATMENT READING
Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.
Not medical advice · Not a complete treatment or trial directory
Made by Triangle.
Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.
Source: Childhood Multiple Endocrine Neoplasia (MEN) Syndromes Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 3, 2025. Captured 2026-09-09.
Cancer in children and adolescents is rare, although the overall incidence has slowly increased since 1975.[1] Children and adolescents with cancer should be referred to medical centers that have a multidisciplinary team of cancer specialists with experience treating the cancers that occur during childhood and adolescence. This multidisciplinary team approach incorporates the skills of the following pediatric specialists and others to ensure that children receive treatment, supportive care, and rehabilitation to achieve optimal survival and quality of life:
Sources: 1
Primary care physicians.
Pediatric surgeons.
Pathologists.
Pediatric radiation oncologists.
Pediatric medical oncologists and hematologists.
Ophthalmologists.
Rehabilitation specialists.
Pediatric oncology nurses.
Social workers.
Child-life professionals.
Psychologists.
Nutritionists.
For specific information about supportive care for children and adolescents with cancer, see the summaries on Supportive and Palliative Care.
Sources: Supportive and Palliative Care
The American Academy of Pediatrics has outlined guidelines for pediatric cancer centers and their role in the treatment of children and adolescents with cancer.[2] At these centers, clinical trials are available for most types of cancer that occur in children and adolescents, and the opportunity to participate is offered to most patients and their families. Clinical trials for children and adolescents diagnosed with cancer are generally designed to compare potentially better therapy with current standard therapy. Other types of clinical trials test novel therapies when there is no standard therapy for a cancer diagnosis. Most of the progress in identifying curative therapies for childhood cancers has been achieved through clinical trials. Information about ongoing clinical trials is available from the NCI website.
Sources: 2 · NCI website
Dramatic improvements in survival have been achieved for children and adolescents with cancer. Between 1975 and 2020, childhood cancer mortality decreased by more than 50%.[3-5] Childhood and adolescent cancer survivors require close monitoring because side effects of cancer therapy may persist or develop months or years after treatment. For information about the incidence, type, and monitoring of late effects in childhood and adolescent cancer survivors, see Late Effects of Treatment for Childhood Cancer.
Sources: 3 · 5 · Late Effects of Treatment for Childhood Cancer
Childhood cancer is a rare disease, with about 15,000 cases diagnosed annually in the United States in individuals younger than 20 years.[6] The U.S. Rare Diseases Act of 2002 defines a rare disease as one that affects populations smaller than 200,000 people in the United States. Therefore, all pediatric cancers are considered rare.
Sources: 6 · Rare Diseases Act of 2002
The designation of a rare tumor is not uniform among pediatric and adult groups. In adults, rare cancers are defined as those with an annual incidence of fewer than six cases per 100,000 people. They account for up to 24% of all cancers diagnosed in the European Union and about 20% of all cancers diagnosed in the United States.[7,8] In children and adolescents, the designation of a rare tumor is not uniform among international groups, as follows:
A consensus effort between the European Union Joint Action on Rare Cancers and the European Cooperative Study Group for Rare Pediatric Cancers estimated that 11% of all cancers in patients younger than 20 years could be categorized as very rare. This consensus group defined very rare cancers as those with annual incidences of fewer than two cases per 1 million people. However, three additional histologies (thyroid carcinoma, melanoma, and testicular cancer) with incidences of more than two cases per 1 million people were also included in the very rare group due to a lack of knowledge and expertise in the management of these tumors.[9]
Sources: 9
The Children's Oncology Group defines rare pediatric cancers as those listed in the International Classification of Childhood Cancer subgroup XI, which includes thyroid cancers, melanomas and nonmelanoma skin cancers, and multiple types of carcinomas (e.g., adrenocortical carcinomas, nasopharyngeal carcinomas, and most adult-type carcinomas such as breast cancers and colorectal cancers).[10] These diagnoses account for about 5% of the cancers diagnosed in children aged 0 to 14 years and about 27% of the cancers diagnosed in adolescents aged 15 to 19 years.[4] Most cancers in subgroup XI are either melanomas or thyroid cancers, with other cancer types accounting for only 2% of the cancers diagnosed in children aged 0 to 14 years and 9.3% of the cancers diagnosed in adolescents aged 15 to 19 years.
These rare cancers are extremely challenging to study because of the relatively few patients with any individual diagnosis, the predominance of rare cancers in the adolescent population, and the small number of clinical trials for adolescents with rare cancers.
This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.
Source: Childhood Multiple Endocrine Neoplasia (MEN) Syndromes Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 3, 2025. Captured 2026-09-09.
Treatment options for childhood MEN syndromes, according to type, are as follows:
Source: Childhood Multiple Endocrine Neoplasia (MEN) Syndromes Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 3, 2025. Captured 2026-09-09.
The treatment of patients with MEN1 syndrome is based on the type of tumor. The outcomes of patients with MEN1 syndrome are generally good, provided adequate treatment can be obtained for parathyroid, pancreatic, and pituitary tumors.
The standard approach to patients who present with hyperparathyroidism and MEN1 syndrome is genetic testing and treatment with a cervical resection of at least three parathyroid glands and transcervical thymectomy.[1]
Sources: 1
For more information, see the Interventions section in Genetics of Endocrine and Neuroendocrine Neoplasias.
Sources: Interventions
Source: Childhood Multiple Endocrine Neoplasia (MEN) Syndromes Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 3, 2025. Captured 2026-09-09.
The management of medullary thyroid cancer in children from families with MEN2 syndromes relies on presymptomatic detection of the RET proto-oncogene variant responsible for the disease.
Source: Childhood Multiple Endocrine Neoplasia (MEN) Syndromes Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 3, 2025. Captured 2026-09-09.
For children with MEN2A syndrome, thyroidectomy is commonly performed by approximately age 5 years or older if that is when a RET variant is identified.[2-7] The outcomes for patients with MEN2A syndrome are generally good, although medullary thyroid carcinoma and pheochromocytoma can recur.[8-10]
A retrospective analysis identified 262 patients with MEN2A syndrome.[11] The median age of the cohort was 42 years and ranged from age 6 to 86 years. There was no correlation between the specific RET variant identified and the risk of distant metastasis. Younger age at diagnosis increased the risk of distant metastasis.
Sources: 11
Source: Childhood Multiple Endocrine Neoplasia (MEN) Syndromes Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 3, 2025. Captured 2026-09-09.
Patients with MEN2B syndrome have worse outcomes than those with MEN2A syndrome, primarily because medullary thyroid carcinoma is more aggressive. Because of the increased severity of medullary thyroid carcinoma in children with MEN2B syndrome and in those with RET variants in codons 883, 918, and 922, it is recommended that these children undergo prophylactic thyroidectomy in infancy.[3,16,17]; [18][Level of evidence C2] This therapy can improve outcomes in patients with MEN2B syndrome.[19] Complete removal of the thyroid gland is recommended because of a high incidence of bilateral disease.
Source: Childhood Multiple Endocrine Neoplasia (MEN) Syndromes Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 3, 2025. Captured 2026-09-09.
Targeted therapy has been used for patients with the RET gene variant and medullary thyroid cancer. Types of targeted therapy include the following:
Source: Childhood Multiple Endocrine Neoplasia (MEN) Syndromes Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 3, 2025. Captured 2026-09-09.
Vandetanib is a selective kinase inhibitor of RET, vascular endothelial growth factor receptor, and epidermal growth factor receptor.
A randomized phase III trial included adult patients with unresectable locally advanced or metastatic (hereditary or sporadic) medullary thyroid carcinoma who were treated with either vandetanib or placebo.[20]
Sources: 20
The study found that vandetanib administration was associated with significant improvements in progression-free survival (PFS), response rate, disease control rates, and biochemical response.
Children with locally advanced or metastatic medullary thyroid carcinoma were treated with vandetanib in a phase I/II trial.[21]
Sources: 21
Of 16 patients, only the one patient without the M918T RET variant had no response.
Of the 15 patients who had tumor responses, seven had partial responses.
Three of the 15 patients had subsequent disease recurrences.
Eleven of the 16 patients treated with vandetanib remained on therapy at the time of the report.
A subsequent follow-up analysis of this cohort plus one additional patient revealed that 10 of the 17 patients achieved partial responses, and an additional 6 individuals had stable disease. The median PFS for these patients was 6.7 years.[22]
Sources: 22
Source: Childhood Multiple Endocrine Neoplasia (MEN) Syndromes Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 3, 2025. Captured 2026-09-09.
Cabozantinib is a tyrosine kinase inhibitor (TKI) that targets three relevant pathways in medullary thyroid carcinoma: MET, VEGFR2, and RET.
In a phase I study, cabozantinib demonstrated promising clinical activity in a cohort of heavily pretreated patients with medullary thyroid carcinoma.[23]
Sources: 23
A double-blind phase III trial compared cabozantinib with placebo in adults with progressive, metastatic medullary thyroid carcinoma.[24]
Sources: 24
The estimated PFS was 11.2 months for patients who received cabozantinib and 4 months for patients who received a placebo.
At 1 year, 47.3% of patients who were treated with cabozantinib were alive and progression free, compared with 7.2% of patients who received a placebo.
Significant adverse effects resulted in dose reductions in 79% of patients and discontinuation of cabozantinib in 16% of patients.
Source: Childhood Multiple Endocrine Neoplasia (MEN) Syndromes Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 3, 2025. Captured 2026-09-09.
Selpercatinib is a RET inhibitor.
A phase I/II trial of selpercatinib therapy included patients with cancers and RET variants. The study enrolled 55 patients with medullary thyroid cancer (age range, 17–84 years) who were previously treated with vandetanib and/or cabozantinib and 88 patients with medullary thyroid cancer (age range, 15–82 years) who were not previously treated with vandetanib or cabozantinib.[25]
Sources: 25
For the previously treated cohort, 69% of patients achieved objective responses, and the median duration of response had not been reached, with a median follow-up of 14 months.
For the cohort who were not previously treated, 73% of patients achieved objective responses, with a median duration of response of 22.0 months.
The most common grades 3 to 4 treatment-related adverse events were hypertension (12%), increased alanine aminotransferase (10%) and aspartate aminotransferase (7%), diarrhea (3%), and prolonged QT interval (2%).
The U.S. Food and Drug Administration granted traditional approval to selpercatinib for the treatment of adult and pediatric patients aged 2 years and older with advanced or metastatic RET-variant medullary thyroid cancer who require systemic therapy.[26]
Sources: 26
Source: Childhood Multiple Endocrine Neoplasia (MEN) Syndromes Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 3, 2025. Captured 2026-09-09.
Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.
Sources: NCI website · ClinicalTrials.gov website
Source: Childhood Multiple Endocrine Neoplasia Type 1 (MEN1) Syndrome, National Cancer Institute.
Source updated: Not stated in this source. Captured 2026-09-09.
Treatment of children with tumors caused by MEN1 syndrome
There are different types of treatment for children and adolescents with tumors caused by MEN1 syndrome. You and your child's cancer care team will work together to decide treatment. Many factors will be considered, such as your child's overall health and whether the cancer is newly diagnosed or has come back.
Your child's treatment plan will include information about the tumor, the goals of treatment, treatment options, and the possible side effects. It will be helpful to talk with your child's cancer care team before treatment begins about what to expect. For help every step of the way, see our booklet, Children with Cancer: A Guide for Parents.
Surgery may be used to treat hyperparathyroidism, which is the most common sign of MEN1 syndrome. Children with MEN1 syndrome and primary hyperthyroidism may have surgery to remove at least three parathyroid glands and the thymus. Treatment is also given for pancreatic islet cell and pituitary tumors, and other conditions linked to MEN1 syndrome as needed.
Sources: islet cell · pituitary tumors
If the cancer comes back after treatment, your child's doctor will talk with you about what to expect and possible next steps. There might be treatment options that may shrink the cancer or control its growth. If there are no treatments, your child can receive care to control symptoms from cancer so they can be as comfortable as possible.
Source: Childhood Multiple Endocrine Neoplasia Type 2 (MEN2) Syndrome, National Cancer Institute.
Source updated: Not stated in this source. Captured 2026-09-09.
Types of treatment for children with tumors caused by MEN2 syndrome
There are different types of treatment for children and adolescents with tumors related to MEN2 syndrome. You and your child's cancer team will work together to decide treatment. Many factors will be considered, such as your child's overall health and whether the cancer is newly diagnosed or has come back.
Your child’s treatment plan will include information about the cancer, the goals of treatment, treatment options, and the possible side effects. It will be helpful to talk with your child’s cancer care team before treatment begins about what to expect. For help every step of the way, see our booklet, Children with Cancer: A Guide for Parents.
Types of treatment your child might have include:
Source: Childhood Multiple Endocrine Neoplasia Type 2 (MEN2) Syndrome, National Cancer Institute.
Source updated: Not stated in this source. Captured 2026-09-09.
Surgery may be done to remove the thyroid gland when a child has medullary thyroid cancer caused by MEN2 syndromes. The thyroid may also be removed to prevent medullary thyroid cancer from developing.
Source: Childhood Multiple Endocrine Neoplasia Type 2 (MEN2) Syndrome, National Cancer Institute.
Source updated: Not stated in this source. Captured 2026-09-09.
Targeted therapy uses drugs or other substances to block the action of specific enzymes, proteins, or other molecules involved in the growth of tumor cells.
Sources: enzymes
Selpercatinib and vandetanib are used to treat medullary thyroid cancer caused by MEN2 syndrome.
Sources: Selpercatinib · vandetanib
Learn more about Targeted Therapy to Treat Cancer.
Sources: Targeted Therapy to Treat Cancer
Source: Childhood Multiple Endocrine Neoplasia Type 2 (MEN2) Syndrome, National Cancer Institute.
Source updated: Not stated in this source. Captured 2026-09-09.
For some children, joining a clinical trial may be an option. There are different types of clinical trials for childhood cancer. For example, a treatment trial tests new treatments or new ways of using current treatments. Supportive care and palliative care trials look at ways to improve quality of life, especially for those who have side effects from cancer and its treatment.
You can use the clinical trial search to find NCI-supported cancer clinical trials accepting participants. The search allows you to filter trials based on the type of cancer, your child's age, and where the trials are being done. Clinical trials supported by other organizations can be found on the ClinicalTrials.gov website.
Sources: clinical trial search · ClinicalTrials.gov
Learn more about clinical trials, including how to find and join one, at Cancer Clinical Trial Information for Patients and Caregivers.
Sources: Cancer Clinical Trial Information for Patients and Caregivers
Source: Childhood Multiple Endocrine Neoplasia Type 2 (MEN2) Syndrome, National Cancer Institute.
Source updated: Not stated in this source. Captured 2026-09-09.
There is an increased risk of medullary thyroid cancer, an aggressive form of thyroid cancer, in people with MEN2A syndrome. Children with MEN2A syndrome and certain changes in the RET gene usually have surgery to remove the thyroid before age 5 years to lessen the chance cancer will form or spread. Treatment is also given for pheochromocytoma and hyperparathyroidism as needed.
Sources: hyperparathyroidism
Treatment of medullary thyroid cancer in children who have MEN2A syndrome may include:
surgery to remove the thyroid
targeted therapy with selpercatinib
Sources: selpercatinib
Source: Childhood Multiple Endocrine Neoplasia Type 2 (MEN2) Syndrome, National Cancer Institute.
Source updated: Not stated in this source. Captured 2026-09-09.
There is an increased risk of medullary thyroid cancer, an aggressive form of thyroid cancer, in people with MEN2B syndrome. Infants with MEN2B syndrome and certain changes in the RET gene usually have surgery to remove the thyroid to lessen the chance cancer will form. Treatment is also given for pheochromocytoma and other conditions as needed.
Children with MEN2B syndrome who have medullary thyroid cancer may be treated with:
surgery to remove the thyroid
targeted therapy with vandetanib or selpercatinib
Sources: vandetanib · selpercatinib
Source: Childhood Multiple Endocrine Neoplasia Type 2 (MEN2) Syndrome, National Cancer Institute.
Source updated: Not stated in this source. Captured 2026-09-09.
If the cancer linked to MEN2 syndrome comes back after treatment, your child’s doctor will talk with you about what to expect and possible next steps. There might be treatment options that may shrink the cancer or control its growth. If there are no treatments, your child can receive care to control symptoms from cancer so they can be as comfortable as possible.
Hyperparathyroidism, Hypercalcemia, Parathyroid Neoplasm, Multiple Endocrine Neoplasia, MEN1
ClinicalTrials.gov recordMultiple Endocrine Neoplasia (MEN) Syndromes in children and adolescents
Treatment of recurrent tumors caused by childhood MEN2 syndrome